17 citations
,
January 2020 in “The World Journal of Men's Health” This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.
20 citations
,
August 2018 in “The World Journal of Men's Health” This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.
71 citations
,
November 2012 in “Expert Opinion on Drug Safety” This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.
124 citations
,
March 2012 in “JAMA” This abstract discusses the unclear role of dihydrotestosterone (DHT) in postembryonic life in marsupials and possibly humans, reporting no new findings.
506 citations
,
March 2005 in “The Journal of Clinical Endocrinology and Metabolism” This study found that testosterone therapy improved physical performance and strength in older men with low testosterone over 36 months, whether administered alone or with finasteride.
26 citations
,
July 1995 in “Neurobiology of Aging” Finasteride affects prostate weights and pituitary activity differently with age.
1040 citations
,
October 1992 in “The New England Journal of Medicine” In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.